Ventilatory support has been a major reason for hospitalization in intensive care units
(ICU) since the creation of these units, which came about precisely for that immediate need
during the polio epidemic in Europe.( In 1967, Ashbaugh described a series of
severe cases marked by respiratory failure, cyanosis, hypoxemia refractory to oxygen
therapy and high mortality, a condition that became known as acute respiratory distress
syndrome (ARDS).( Almost 50 years after
the syndrome was first identified, the treatment of ARDS is still a major challenge for
intensive care medicine and continues to be associated with high mortality and
morbidity.( Several therapeutic modalities have been proposed, with
variable results, including in terms of cost. These therapies involve mechanical
ventilation strategies,( patient positioning,( and the use of medications and gas mixtures,(
among other techniques. Recently, extracorporeal membrane oxygenation (ECMO) therapy has
once again become popular.(ECMO, arising from surgery requiring cardiopulmonary bypass, has been used as a treatment
for ARDS since the 1970s,( with
unfavorable initial results.( However, the therapy was never
definitively abandoned and, in 2009, with the influenza A (H1N1) pandemic, the use of ECMO
showed more promising results in large case series in developed countries.( The exchange of information between
centers with experience in the method and professional qualifications clearly contributed
to these results. In Brazil, the Park group( and others( have
demonstrated the feasibility of using the technique to support patients with ARDS
refractory to conventional treatment in our units. However, in our country, this know-how
is restricted to a few groups, and the use of ECMO in most services remains just a
possibility.The incorporation of the new therapeutic modalities, especially when they are invasive and
incur a significant risk to the patient, presents a dilemma in the care team's decision
making. Even when efficacy data from controlled studies are available, it is natural that
the physician and the multidisciplinary team may hesitate to adopt measures that are still
not widely used in their field.(From the manager's point of view, the dilemma may be even harder to resolve. Incorporating
a new technology that requires significant resources can result in a lack of resources for
other care activities that are already in place. Unlike the care team, the manager has
fewer elements within the scientific literature upon which to base his or her decision and
often must be guided by unmeasurable elements, which leads to the high likelihood of
cognitive bias. A recent survey shows that the incorporation of health technology in the
hospital setting rarely relies on cost-effectiveness analyses.( The study by Park et al. in this volume of RBTI may be one
of the few elements that can help managers to make quantitatively justifiable decisions in
this regard.(The study suggests that ECMO has an acceptable cost-effectiveness ratio in our environment
and that in some hypothetical scenarios, it has demonstrated a capacity to save resources
while improving adjusted survival rates. We should emphasize that economic analyses in the
health field must be performed with parameters (especially those pertaining to cost)
specific to the region in question. Unlike clinical efficacy studies, the possibility of
generalizing results obtained in distant countries is very small because there are
differences with respect to both individual cost values of therapeutic elements and the
number of elements used in the situations studied.As the authors admit from the start of the article, the analysis presented is not
definitive. However, it does bring to light an important issue in intensive care medicine
from a little explored point of view - especially in the areas of techniques and equipment.
An empirical study on this topic would still be interesting, but as of this moment, the
authors have provided elements for making a more soundly based decision.
Authors: Laurent Papazian; Jean-Marie Forel; Arnaud Gacouin; Christine Penot-Ragon; Gilles Perrin; Anderson Loundou; Samir Jaber; Jean-Michel Arnal; Didier Perez; Jean-Marie Seghboyan; Jean-Michel Constantin; Pierre Courant; Jean-Yves Lefrant; Claude Guérin; Gwenaël Prat; Sophie Morange; Antoine Roch Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: Moronke A Noah; Giles J Peek; Simon J Finney; Mark J Griffiths; David A Harrison; Richard Grieve; M Zia Sadique; Jasjeet S Sekhon; Daniel F McAuley; Richard K Firmin; Christopher Harvey; Jeremy J Cordingley; Susanna Price; Alain Vuylsteke; David P Jenkins; David W Noble; Roxanna Bloomfield; Timothy S Walsh; Gavin D Perkins; David Menon; Bruce L Taylor; Kathryn M Rowan Journal: JAMA Date: 2011-10-05 Impact factor: 56.272
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: A H Morris; C J Wallace; R L Menlove; T P Clemmer; J F Orme; L K Weaver; N C Dean; F Thomas; T D East; N L Pace; M R Suchyta; E Beck; M Bombino; D F Sittig; S Böhm; B Hoffmann; H Becks; S Butler; J Pearl; B Rasmusson Journal: Am J Respir Crit Care Med Date: 1994-02 Impact factor: 21.405
Authors: Andrew Davies; Daryl Jones; Michael Bailey; John Beca; Rinaldo Bellomo; Nikki Blackwell; Paul Forrest; David Gattas; Emily Granger; Robert Herkes; Andrew Jackson; Shay McGuinness; Priya Nair; Vincent Pellegrino; Ville Pettilä; Brian Plunkett; Roger Pye; Paul Torzillo; Steve Webb; Michael Wilson; Marc Ziegenfuss Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: Marcelo Park; Pedro Vitale Mendes; Fernando Godinho Zampieri; Luciano Cesar Pontes Azevedo; Eduardo Leite Vieira Costa; Fernando Antoniali; Gustavo Calado de Aguiar Ribeiro; Luiz Fernando Caneo; Luiz Monteiro da Cruz Neto; Carlos Roberto Ribeiro Carvalho; Evelinda Marramon Trindade Journal: Rev Bras Ter Intensiva Date: 2014 Jul-Sep